AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

Front Pharmacol · 2021 · PMC8118639 · PMID 33995085

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Updated results after 40 months of follow-up showed a favorable trend in terms of OS for capivasertib plus paclitaxel, regardless of the PIK3CA/AKT/PTEN mutational status (median OS in the overall population 19.1 months vs. 13.5 months; HR 0.7; 95% CI: 0.47–1.05; p = 0.085) ( Schmid et al., 2021a ).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.